grey arrow to go to previous Omnicell webpage or forward to next Omnicell pageBack to Blog

April 21, 2020

Visibility to COVID-19 Medication Inventory

Arash Dabestani, Senior Director of Pharmacy at NYU Langone, outlined emerging needs such as efficiently tracking daily COVID-19 inventory levels, reducing stocking frequencies in isolation areas, and preparing the right medications for new units, in his Notes from the Epicenter.

To help address these challenges, Omnicell worked with pharmacy leaders and industry associations, including the Society of Critical Care Medicine, in order to determine the critical medications needed for COVID-19 patients. Research focused on drugs used to treat acute respiratory distress syndrome and medications reported as being used to treat COVID-19 in other countries. The resulting medication list was extensively validated with customers, including those in current epicenters. Continual refinements are being made based on emerging evidence and additional customer feedback.

We are providing this targeted list in the form of ready-to-use reports to quickly help you get a holistic view of your inventory levels and the forecasted burn rate of 75+ medications related to COVID-19. This reporting will help you make faster, more informed decisions:

  • Redeploy critical medication where it's needed the most
  • Increase par levels in isolation/ICU areas to reduce stocking frequencies
  • Actively plan to safeguard COVID-19 medications and project potential shortage situations
  • Easily forward top-line summary of needs to leadership

Customers can get the list and implement the reporting themselves by downloading the templates on myomnicell.com. We are also launching daily automated emails to a continually expanding group of customers to facilitate this process.

Stay tuned for more enhancements to follow.


The views and opinions expressed in this blog are those of the authors and do not necessarily reflect the official policy or position of any other agency, organization, employer or company. Assumptions made in the analysis are not reflective of the position of any entity other than the author(s). These views are always subject to change, revision, and rethinking at any time and may not be held in perpetuity.